The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
and that is wicked hard because you've got the therapeutic and the diagnostic at the same time now things like CD20 things like VEGF are very ubiquitous so it's not really targeted in the sense of her two um where we needed a diagnostic but if you need to have that
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
And the other thing that's essential is and especially modern oncology if you have a targeted therapy you must have a diagnostic and that is wicked hard because you've got the therapeutic and the diagnostic at the same time.